226 Poster - Finding existing drugs potentially active against BRCA-mutated breast cancers: A literature-based approach

Abstract

Background: Mutations in the BRCA genes predispose to developing breast, ovarian and other cancers. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are one treatment option in BRCA-mutated cancers, as are platinum salts since they induce DNA breaks that then require proficient BRCA for repair. Next to this “soft” repurposing – using an anticancer drug to treat another cancer – we sought to identify “hard” repurposing opportunities – using non-cancer drugs, here in BRCA-mutated tumors.